fda approves first oral glp-1 obesity drug august 1 2025 The Next Wave of Treatment: Medications Novo's Wegovy becomes first GLP-1

Many patients notice improved sleep within the first few weeks, with recovery and energy becoming more apparent over one to two months

Not all doctors are convinced these costs are worth it, though

It can cause muscle weakness

Hiromichi Wakui has received research supports from AstraZeneca, Otsuka Pharmaceutical, and Kaneka Corporation, and honoraria from AstraZeneca, Otsuka Pharmaceutical, Kaneka Corporation, Kyowa Kirin, Sanwa Kagaku, Chugai Pharma, Kowa, Otsuka Pharmaceutical, Novartes, Mitsubishi-Tanabe Pharma, Bayer, and Daiichi-Sankyo Pharma

Studies have shown that muscle fatigue can be delayed by boosting glutathione levels

It is not simply a "stronger ghrelin receptor agonist"